Dyspepsia Drug Development – 2018 Pipeline Analysis Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “2018
Dyspepsia Drug Development- Pipeline Analysis Report”
report
has been added to ResearchAndMarkets.com’s offering.

To assist investigators and funding and regulatory organizations, the
publisher has come up with a comprehensive report on Dyspepsia pipeline.
The report provides insights into different therapeutic candidates in
preclinical, research, discovery, NDA/IND, pre registration, phase 1,
phase 2, and phase 3 trials). Drugs under development directly and
through combination with other drugs are also included.

Current status, developmental phase, participating companies and
entities, recent developments, orphan drug/ fast track/ other
designations, drug class are provided for each Dyspepsia pipeline
product. Mechanism of Action and the target area of the pipeline product
are also provided. Further, clinical and preclinical trials along with
results of the trials are also included in the report.

In addition to complete details of each product, the report provides key
trends in Dyspepsia pipeline studies. The products under development are
categorized according to their development phase, mechanism and company
to provide detailed insights into the type of drugs being developed and
the stages of development.

Key Topics Covered:

1 Dyspepsia Pipeline Analysis

2 Dyspepsia – Company Wise Pipeline Analysis

3 Dyspepsia R&D Pipeline Snapshots

4 Recent Developments in Dyspepsia Pipeline

5 Appendix

Companies Featured

  • Abide Therapeutics
  • Daewoong Pharmaceutical Co Ltd
  • Dong-A ST Co., Ltd.
  • IlDong Pharmaceutical Co Ltd
  • LTT Bio-Pharma Co Ltd
  • RaQualia Pharma Inc
  • Renexxion LLC
  • Rottapharm
  • Zensun (Shanghai) Sci & Tech
  • Zeria Pharmaceutical Co Ltd

For more information about this report visit https://www.researchandmarkets.com/research/nvxff9/dyspepsia_drug?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Drug
Discovery
, Gastrointestinal
Drugs